Sign In
Buy PRCT
$16.69
-0.86 (-4.90%)
At Close: Jul 24, 2026
Procept BioRobotics resumed with an Overweight at Wells Fargo
05:46am, Tuesday, 03'rd Dec 2024
Wells Fargo resumed coverage of Procept BioRobotics with an Overweight rating and $112 price target. The firm believes aquablation remains early stages in its adoption, which will be further supported
PROCEPT BioRobotics to Present at Upcoming 36th Annual Piper Sandler Healthcare Conference on December 4, 2024
04:05pm, Tuesday, 26'th Nov 2024
SAN JOSE, Calif., Nov. 26, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing transformative
Procept BioRobotics: Continued Growth Runway Ahead
05:10am, Tuesday, 26'th Nov 2024
PRCT's Q3 sales were up 66% YoY, and gross margins reached a record 63%. Management forecasts $223mm in sales this year, with a 64% top-line growth. The business model ensures recurring revenue and op
Are You Looking for a Top Momentum Pick? Why PROCEPT BioRobotics Corporation (PRCT) is a Great Choice
01:00pm, Thursday, 07'th Nov 2024
Does PROCEPT BioRobotics Corporation (PRCT) have what it takes to be a top stock pick for momentum investors? Let's find out.
PROCEPT BioRobotics Corporation Announces Pricing of Offering of Common Stock
08:43pm, Tuesday, 29'th Oct 2024
SAN JOSE, Calif., Oct. 29, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing
All You Need to Know About PROCEPT BioRobotics (PRCT) Rating Upgrade to Strong Buy
01:01pm, Tuesday, 29'th Oct 2024
PROCEPT BioRobotics (PRCT) has been upgraded to a Zacks Rank #1 (Strong Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
PROCEPT BioRobotics Corporation Announces Proposed Offering of Common Stock
04:19pm, Monday, 28'th Oct 2024
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (NASDAQ: PRCT) (“PROCEPT BioRobotics” or the “Company”), a surgical robotics company focused on advancing
Surgical Robotics Provider PROCEPT BioRobotics' Q3 Earnings Beats Street View, Analyst Optimistic About Upside Potential
02:17pm, Monday, 28'th Oct 2024
PROCEPT BioRobotics PRCT stock is trading on Monday after the company released better-than-expected third-quarter earnings.
PROCEPT BioRobotics Corporation (PRCT) Q3 2024 Earnings Call Transcript
10:32am, Monday, 28'th Oct 2024
PROCEPT BioRobotics Corporation (NASDAQ:PRCT ) Q3 2024 Earnings Conference Call October 28, 2024 8:00 AM ET Company Participants Matt Bacso - Vice President, Investor Relations Reza Zadno - Chief Exec
PROCEPT BioRobotics Corporation (PRCT) Reports Q3 Loss, Tops Revenue Estimates
09:11am, Monday, 28'th Oct 2024
PROCEPT BioRobotics Corporation (PRCT) came out with a quarterly loss of $0.40 per share versus the Zacks Consensus Estimate of a loss of $0.48. This compares to loss of $0.51 per share a year ago.
PROCEPT BioRobotics® Reports Third Quarter 2024 Financial Results and Increases 2024 Revenue and Adjusted EBITDA Guidance
07:00am, Monday, 28'th Oct 2024
SAN JOSE, Calif., Oct. 28, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics Corporation (Nasdaq: PRCT) (the “Company”), a surgical robotics company focused on advancing patient care by developing tran
Down -15.71% in 4 Weeks, Here's Why PROCEPT BioRobotics (PRCT) Looks Ripe for a Turnaround
10:35am, Friday, 25'th Oct 2024
PROCEPT BioRobotics (PRCT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings
PROCEPT BioRobotics Corporation (PRCT) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
11:05am, Monday, 21'st Oct 2024
PROCEPT BioRobotics (PRCT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
PROCEPT BioRobotics to Report Third Quarter 2024 Financial Results on October 28, 2024
04:04pm, Wednesday, 09'th Oct 2024
SAN JOSE, Calif., Oct. 09, 2024 (GLOBE NEWSWIRE) -- PROCEPT BioRobotics® Corporation (the “Company”) (Nasdaq: PRCT), a surgical robotics company focused on advancing patient care by developing tr
PRCT Stock Rises on FDA's Nod to Initiate Study on Prostate Cancer
01:45pm, Tuesday, 08'th Oct 2024
PROCEPT BioRobotics receives FDA's approval to begin a pivotal randomized clinical study to assess the use of Aquablation therapy in treating prostate cancer patients.
